AvalehtSH0 • FRA
add
Shionogi & Co Ltd
Viimane sulgemishind
13,90 €
Tänane vahemik
13,70 € - 13,70 €
Aasta vahemik
11,67 € - 15,60 €
Turuväärtus
2,08 trln JPY
Keskmine maht
33,00
P/E suhe
-
Dividendimäär
-
Põhibörs
TYO
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(JPY) | märts 2025info | Y/Y muutus |
---|---|---|
Käive | 104,70 mld | 6,55% |
Põhitegevusega seonduv kulu | 59,56 mld | 11,50% |
Puhastulu | 36,60 mld | 5,14% |
Puhaskasumimarginaal | 34,95 | −1,33% |
Puhaskasum aktsia kohta | — | — |
EBITDA | 32,81 mld | −4,96% |
Tõhus maksumäär | 19,32% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(JPY) | märts 2025info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 374,80 mld | 4,67% |
Kogu vara | 1,54 trln | 8,35% |
Kõik kohustused | 172,80 mld | 5,14% |
Kogu omakapital | 1,36 trln | — |
Emiteeritud aktsiate arv | 850,69 mln | — |
Hinna ja väärtuse suhe P/B | 0,01 | — |
Varade tasuvus | 4,48% | — |
Kapitali tasuvus | 4,94% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(JPY) | märts 2025info | Y/Y muutus |
---|---|---|
Puhastulu | 36,60 mld | 5,14% |
Põhitegevuse rahakäive | — | — |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | — | — |
Tasuta rahavoog | — | — |
Teave
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Tegevjuht
Asutatud
1878
Peakontor
Veebisait
Töötajate arv
4 955